GlassScriptPhysician profile
John S Mccomb
NPI 1689666133
$1,979.69
in general payments reported to CMS, 2019-2025
33 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $113 · 2021: $208 · 2022: $342 · 2023: $235 · 2024: $394 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $625.27 | 2019-2023 | |
| Astellas Pharma US INC | $214.51 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $179.57 | 2023-2025 | |
| Avion Pharmaceuticals | $114.28 | 2019-2022 | |
| Evofem Biosciences, INC. | $83.60 | 2021-2025 | Phexxi, Solosec, Phexx |
| Biogen, INC. | $78.84 | 2024-2025 | Zurzuvae |
| Lilly USA, LLC | $58.80 | 2024-2025 | Zepbound |
| Allergan, INC. | $47.48 | 2019 | |
| Exeltis, USA INC. | $45.80 | 2019-2024 | Slynd |
| Pfizer INC. | $45.00 | 2021-2025 | |
| Therapeuticsmd, INC. | $39.79 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $36.29 | 2019-2021 | |
| Daiichi Sankyo INC. | $36.05 | 2019-2024 | Injectafer |
| Lupin INC. | $35.45 | 2019 | |
| Eisai INC. | $29.14 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $25.91 | 2019 | |
| Merck Sharp & Dohme LLC | $25.62 | 2019-2020 | |
| Duchesnay USA Incorporated | $24.87 | 2019 | |
| Cepheid | $21.71 | 2024 | Genexpert |
| Idorsia Pharmaceuticals US INC | $18.61 | 2022 | |
| Renovia INC | $18.32 | 2021 | |
| Coopersurgical, INC. | $18.01 | 2019 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Organon LLC | $16.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.17 | 2020 | |
| Currax Pharmaceuticals LLC | $14.73 | 2019 | |
| Agile Therapeutics, INC. | $14.55 | 2023 | Twirla |
| Shield Therapeutics INC | $14.34 | 2024 | |
| Sanofi Pasteur INC. | $14.19 | 2025 | |
| Ethicon US, LLC | $13.86 | 2019 | |
| Novo Nordisk INC | $13.44 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.29 | 2020 | |
| Meditrina | $8.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mccomb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.